Biologic disease-modifying antirheumatic drugs (bDMARDs), particularly tumor necrosis factor-alpha (TNF-α) inhibitors, have revolutionized the treatment of various inflammatory rheumatological conditions, including rheumatoid arthritis and juvenile idiopathic arthritis [2]. The gene discussed is TNF; the disease is juvenile idiopathic arthritis.